The goal of this proposal is to evaluate the ability of the antioxidants Vitamin C (ascorbate), Vitamin E (a-tocopherol) and metallothionein (MT) to reduce the frequency and spectrum of spontaneous mutations at the HPRT locus. Ascorbate is anticipated to reduce DNA damage resulting from direct oxidation of the nitrogenous bases, a-tocopherol by blocking DNA adduct formation by lipid peroxidation products and metallothionein by scavenging cellular free radicals. The spectra of spontaneous mutations and pattern of DNA damage will be evaluated in three human cell lines: HCT116, a mismatch repair deficient colon carcinoma cell line; HCT116/ch3, and HCT116 derivative into which an intact human chromosome 3 has been introduced, and SW480, a mismatch repair proficient colon carcinoma cell line. Cells will be incubated with one of the two antioxidants or transfected with a metallothionein expression vector and incubated with Zn, HPRT mutants collected and the mutational spectra and DNA damage profile determined. In addition, the mismatch repair deficient cell line will be evaluated for an undescribed panel of microsatellite markers for determination of whether oxidative damage is a principal cause of microsatellite mutations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA073610-03
Application #
6172888
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Okano, Paul
Project Start
1998-04-01
Project End
2003-03-31
Budget Start
2000-04-01
Budget End
2003-03-31
Support Year
3
Fiscal Year
2000
Total Cost
$323,582
Indirect Cost
Name
New York University
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Li, Ping; Uddin, Ahmed N; Liu, Zijuan et al. (2004) Variability in sensitivity to arsenite does not correlate with arsenic accumulation rate in normal human lymphoblasts. Mol Cell Biochem 255:79-85
Rossman, Toby G; Uddin, Ahmed N; Burns, Fredric J (2004) Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol Appl Pharmacol 198:394-404
Rossman, Toby G (2003) Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 533:37-65
Mure, Kanae; Uddin, Ahmed N; Lopez, Laura C et al. (2003) Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ Mol Mutagen 41:322-31
Mure, K; Rossman, T G (2001) Reduction of spontaneous mutagenesis in mismatch repair-deficient and proficient cells by dietary antioxidants. Mutat Res 480-481:85-95